OncLive.com· @OncLive · X·· 1 天前评分45
正文 · 原文
🧬 What could a CLDN18.2-directed ADC offer patients with previously treated advanced gastric cancer?
At @esmoESMO #ESMO26, phase 3 G-HOPE-001 results highlight the potential of arcotatug tavatecan.
Read more: https://www.onclive.com/view/arcotatug-tavatecan-improves-survival-in-cldn18-2-advanced-gastric-or-gej-adenocarcinoma #oncology
278 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA77按 Proffered paper 1: Gastrointestinal tumour, upper digestive 对上
Arcotatug tavatecan (IBI343/TAK-921) versus treatment of physician’s choice (TPC) in previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA): First interim analysis of the randomized, open-label, phase 3, G
https://esmocongress.esmo.org来源：OncLive.com · x.com